UroGen Pharma Ltd
Research UroGen Pharma Ltd (URGN) on Bullrun: market cap USD 2.27B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerURGN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.27B
- Financial periodQ2 2026
- RevenueUSD 72.46M
- Net income-USD 14.35M
- Free cash flow-USD 33.07M
- Gross margin90.9%
Valuation Snapshot
latest market cap is USD 2.27B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 109.79M | -USD 153.49M | -USD 162.73M | 88.7% | -3.2 | USD 110.75M | USD 122.21M | -USD 105.47M |
| FY2024 | USD 90.40M | -USD 126.87M | -USD 97.06M | 90.2% | -3.09 | USD 171.99M | USD 121.73M | -USD 8.80M |
| FY2023 | USD 82.71M | -USD 102.24M | -USD 76.57M | 88.7% | -6.56 | USD 95.00M | USD 98.55M | -USD 65.21M |
| FY2022 | USD 64.36M | -USD 109.78M | -USD 87.81M | 88.1% | n/a | USD 55.41M | USD 97.54M | -USD 89.36M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.27B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.13B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 449.77M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 462.99M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 204.81M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 213.62M | n/a | n/a | n/a |
About UroGen Pharma Ltd
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is UroGen Pharma Ltd's market cap?
UroGen Pharma Ltd's market capitalization is USD 2.27B.
What does UroGen Pharma Ltd do?
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.